We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-18.48%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$231M
Cap. Flow
+$83.3M
Cap. Flow %
8.09%
Top 10 Hldgs %
74.22%
Holding
35
New
1
Increased
3
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$62.2M
2
TSVT
2seventy bio
TSVT
+$20.9M
3
MRSN
Mersana Therapeutics
MRSN
+$5.31M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$254K

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$5.38M

Sector Composition

Rank Sector Weight
1 Healthcare 94.71%
2 Financials 3.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$273M 26.48%
4,831,307
– –
DVAX
2
DELISTED
Dynavax Technologies
DVAX
$91.2M 8.86%
8,415,000
– –
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$3.26B
$76.6M 7.44%
3,979,292
– –
PHVS icon
4
Pharvaris
PHVS
$2.43B
$57.7M 5.6%
3,180,601
– –
RPID icon
5
Rapid Micro Biosystems
RPID
$85.2M
$57.3M 5.56%
8,434,560
– –
NUVL
6
DELISTED
Nuvalent
NUVL
$47.6M 4.62%
3,428,014
– –
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.93B
$44.6M 4.33%
2,029,701
– –
EQRX
8
DELISTED
EQRx, Inc. Common Stock
EQRX
$41.3M 4.01%
10,003,573
– –
CCCC icon
9
C4 Therapeutics
CCCC
$400M
$39.8M 3.87%
1,642,210
– –
AMLX icon
10
Amylyx Pharmaceuticals
AMLX
$2.53B
$35.4M 3.44%
+2,756,050
New +$62.2M
MRSN
11
DELISTED
Mersana Therapeutics
MRSN
$26M 2.53%
260,881
+45,454
+21% +$5.31M
TSVT
12
DELISTED
2seventy bio
TSVT
$24M 2.33%
1,408,901
+1,229,508
+685% +$20.9M
APTX
13
DELISTED
Aptinyx Inc. Common Stock
APTX
$20.2M 1.96%
8,891,758
– –
XLO icon
14
Xilio Therapeutics
XLO
$60.5M
$19.8M 1.93%
200,387
– –
NRIX icon
15
Nurix Therapeutics
NRIX
$2.69B
$18M 1.75%
1,284,313
– –
AVIR icon
16
Atea Pharmaceuticals
AVIR
$402M
$17.9M 1.74%
2,485,638
– –
SVRA icon
17
Savara
SVRA
$1.17B
$15.2M 1.48%
11,622,598
– –
TNGX icon
18
Tango Therapeutics
TNGX
$4.51B
$14.6M 1.41%
1,921,790
– –
MRNS
19
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$13.4M 1.3%
1,431,058
– –
RACB
20
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$9.76M 0.95%
1,000,000
– –
SLDB icon
21
Solid Biosciences
SLDB
$918M
$9.52M 0.92%
528,661
– –
ANNX icon
22
Annexon
ANNX
$883M
$8.85M 0.86%
3,241,628
– –
IVVD icon
23
Invivyd
IVVD
$198M
$8.83M 0.86%
1,937,207
– –
NAUT icon
24
Nautilus Biotechnolgy
NAUT
$110M
$8.68M 0.84%
2,000,000
– –
SYRS
25
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.46M 0.72%
626,442
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q1 2022 Portfolio in Review

As of Q1 2022, Bain Capital Life Sciences Investors held 35 positions worth $1.03B, down 18% from $1.26B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Bain Capital Life Sciences Investors deployed $83.3M of net new capital in Q1 2022, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Amylyx Pharmaceuticals: 2,756,050 shares worth $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Financials.

On the sell side, the most notable exit was bluebird bio, an estimated $5.38M sold.

  • Bain Capital Life Sciences Investors's largest Q1 2022 buy was Amylyx Pharmaceuticals: 2,756,050 shares worth $35.4M.
  • Bain Capital Life Sciences Investors added most to 2seventy bio in Q1 2022, an estimated $20.9M increase.
  • Bain Capital Life Sciences Investors fully exited bluebird bio in Q1 2022, selling an estimated $5.38M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 74% of its $1.03B portfolio in Q1 2022.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 1 in Q1 2022.
  • Bain Capital Life Sciences Investors's portfolio value fell 18% quarter-over-quarter to $1.03B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2022, filed 16 May 2022.